Teva closes Cidra plant
Teva announces Aug. 23 that it will cease production at its Cidra, Puerto Rico manufacturing facility in the fourth quarter as part of a "globalization rationalization strategy." During a recent earnings call, Teva said it wanted to "significantly reduce complexity" at the facility, which was inherited through its acquisition of Ivax, due to repeated problems (1"The Pink Sheet" Aug. 14, 2006, p. 7). The facility currently employs 550 personnel and originally manufactured 50 products, the majority of which Teva says have been transferred to other sites. The company anticipates the closure will result in approximately $45 mil. in cost savings in 2007...
You may also be interested in...
Teva's supply chain challenges appear to have caught up with the company in the form of further delays of its launch of Zoloft generics
The independent, family-controlled German group has signed a third R&D pact with Danish biotech Gubra to develop poly-agonist peptides for obesity.
Inovio Pharmaceuticals has reported promising initial data from its first Phase III study of its electrical current-driven DNA plasmid-based immunotherapy, VGX-3100, in virus-associated cervical dysplasia; it is heading a small group of companies evaluating novel therapies in the condition, which often advances to cancer.